论文部分内容阅读
辅助生殖技术(ART)的发展为不孕不育夫妇带来了福音,但由于在ART中广泛使用的促排卵药物,如氯米芬、HCG、HMG、rFSH等可使性腺激素水平升高,促排卵药物是否增加乳腺、卵巢、子宫内膜和其他靶器官肿瘤的风险,辅助生殖技术出生的后代是否会增加患恶性肿瘤的风险。本文综述目前的文献资料,多数认为促排卵药物的使用并没有增加乳腺癌、子宫内膜癌、浸润性卵巢癌的风险,卵巢交界性肿瘤的发生率可能增加;辅助生殖技术出生的后代儿童肿瘤的发生率与一般人群相似。对接受人类辅助生殖技术的妇女其肿瘤发生、子代肿瘤的发生应引起高度重视,有待于今后多中心、大样本、长期的随访观察研究。
The development of assisted reproductive technology (ART) has brought gospel to infertile couples, but due to ovulation-promoting drugs such as clomiphene, HCG, HMG and rFSH which are widely used in ART, the level of gonadotropin can be increased, Whether ovulation induction increases the risk of tumors in the breast, ovary, endometrium, and other target organs, whether assisted-born offspring will increase the risk of developing malignancies. This review summarizes the current literature, most believe that the use of ovulation induction drugs did not increase the risk of breast cancer, endometrial cancer, invasive ovarian cancer, the incidence of borderline ovarian cancer may increase; assisted reproductive technology in offspring of children born with tumors The incidence of the general population similar. Women receiving assisted reproductive technology of human tumors, offspring of tumors should be attached great importance to the pending multi-center, large sample, long-term follow-up study.